Cosmos Health Posts 31% Q1 Revenue Growth to $17.9M, Cuts Liabilities by $4.5M
Cosmos Health’s Q1 revenue jumped 30.7% year-over-year to $17.93 million, driven by CosmoFarm expansion, Sky Premium Life growth, and new Cana Labs contracts. Total liabilities fell 9.6% to $42.54 million while stockholders' equity rose 7.6% to $19.83 million, with adjusted EBITDA near breakeven.
1. Record Q1 Financial Performance
Cosmos Health delivered Q1 revenue of $17.93 million, up 30.7% year-over-year, and adjusted revenue of $18.40 million, up 34.2%. Gross profit was $1.38 million GAAP (adjusted $1.85 million), while adjusted EBITDA was near breakeven at a loss of $229,596, reflecting strategic investments that drove a net loss of $2.81 million.
2. Balance Sheet Improvement
Total liabilities dropped by 9.6% to $42.54 million, and stockholders’ equity increased by 7.6% to $19.83 million, improving the liabilities-to-assets ratio by 370 basis points to 68.2%. Liquid assets totaled $4.3 million, including $2.2 million in cash and cash equivalents and $2.1 million in digital assets and marketable securities.
3. Growth Drivers and U.S. Expansion
The company added over 75 pharmacies to its CosmoFarm network, expanded Sky Premium Life order activity, and secured new contract manufacturing agreements at Cana Laboratories. Management highlighted entry into the U.S. nutraceuticals market through its 18 Series platform and ongoing investments in AI, infrastructure, and personnel to support global growth.